Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

BioElectronics Prepares For General Surgical Recovery FDA 510(k) Premarketing Application Submission
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced the Company is currently preparing an application for 510(k) premarket notification for submission to the Food and Drug Administration (FDA) for general surgical recovery. The filing will request an indication for the adjunct of use in palliative treatment of postoperative edema and pain in superficial soft tissue.
generic viagra online
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data For AM211, A Novel Product Candidate For The Treatment Of Respiratory Diseases
Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study of AM211, the company"s oral selective antagonist of the DP2 (also known as CRTH2) receptor.
News of the day
Questioning The Use Of Muscle Rubs
There is not enough evidence to support using gels and creams containing rubefacients for chronic and acute pain, according to a systematic review by Cochrane Researchers. Rubefacients cause irritation and reddening of the skin, due to increased blood flow. The review focused on formulations containing salicylates, which are widely prescribed or sold over the counter as topical treatments for sports injuries and muscle pain.
Nutrition

Fifty One Genes Predict Breast Cancer Survival

It may be possible in the future to use a specimen from the tumour to determine which patients with breast cancer have a good chance of overcoming the disease, and which patients should be given more intensive treatments. Fifty-one genes may together provide information about the prognosis for an individual patient. These are the conclusions of a thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden. The research group has analysed specimens from a number of breast tumours, both from patients that died from the disease and from patients surviving at least 10 years from diagnosis. The levels of expression of 51 genes differed between the two groups. It should be possible to use the differences in order to classify the patients into one of two groups: a favourable prognosis group and a poor prognosis group. "Many breast cancer patients are currently overtreated, while some are undertreated. If it was possible to identify patients with poor prognosis, it would be possible to use greater treatment res on these patients. At the same time, patients with a favourable prognosis could avoid unnecessary treatment", says Elin Karlsson who successfully defended her thesis on June 5. Comparing the amounts of the gene products of these 51 genes with data from a previous study has allowed the research team to show that the genes have the ability to predict survival also for the new material. The research group has also studied the protein BTG2, and shown that it is involved at several levels in the tumours that were examined. The protein was present more often in specimens from patients who had survived at least 5 years after diagnosis than in patients who had died within 5 years from diagnosis. It has been previously determined that this protein is a tumour suppressor, but the study at the Sahlgrenska Academy is the first to indicate it as a prognostic marker. "We consider it to be a promising marker: it will maybe be possible to use it to determine which patients with breast cancer require particularly close surveillance. More research, however, will be required in order to confirm our results before analysis of the protein can be used in the clinic", says Elin Karlsson. University of Gothenburg


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009